Division of WuXi PharmaTech Inc.
Latest From WuXi Biologics
China-focused venture goes against tide by acquiring anti-infective assets via multiple deals that will build out its pipeline in an area deprioritized by big pharma.
Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics
Celltrion and iProgen will co-develop ADC candidates, Miracogen and Synaffix sign a technology license after a successful research collaboration, and WuXi will provide clinical trial material to NBE Therapeutics.
Bharat hopes to expand international reach of Chiron Behring’s rabies vaccine. WuXi and Biolingus partner on sublingual delivery.
Already having launched several portfolio companies, Roivant goes a step further by spinning out CNS specialist Arvelle from Axovant. BI and IBM will incorporate blockchain technology in clinical trials, while AbbVie licenses multiple myeloma candidate from TeneoBio.
- Large Molecule
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Parent & Subsidiaries
- WuXi PharmaTech Inc.
- Senior Management
Zhisheng Chen, PhD, CEO
Christine Lu-Wong, EVP, CFO
Weichang Zhou, PhD, SVP, CTO
- Contact Info
Phone: 510 8183 1205
108 Meiliang Road. W
Wuxi , 214092
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.